Adding NAD+ IV therapy to your medspa's menu in 2026 means more than buying a compounding source and training a nurse — it means solving the medical oversight question before your first patient rolls up a sleeve.
- Adding NAD+ IV therapy to a medspa menu requires a signed collaborating physician agreement covering IV nutrient therapy specifically — generic Botox-only agreements don’t cover it.
- Good faith exams and a NAD+-specific standing order come before your first patient, not after launch.
- US Medical Directors can structure oversight for NAD+ IV therapy alongside existing services — verdict: build the compliance layer first, market second.
- Chart review documentation for NAD+ infusions needs its own protocol distinct from injectables or weight loss chart review.
Why this matters
NAD+ IV therapy sits in a gray zone in most state medical practice acts. It's an IV infusion, which in nearly every state requires a physician order or a nurse practitioner operating under a collaborating physician agreement broad enough to cover infusion therapy.
Medspas that already run Botox and filler under one collaborating physician agreement often assume that same agreement covers NAD+. It usually doesn't. NAD+ is a different route of administration, a different informed consent, and a different adverse-event profile than a neurotoxin injection — and state boards look at that distinction when a complaint lands on their desk.
The practices that add NAD+ IV therapy smoothly in 2026 do the paperwork before the marketing. The ones that get flagged skip straight to the Instagram post.
What you'll need
- A collaborating physician agreement or medical director contract that explicitly names IV nutrient therapy, not just injectables
- A NAD+-specific standing order or protocol, signed by your supervising physician
- Good faith exam documentation for every new NAD+ patient before the first infusion
- A chart review workflow that captures NAD+ visits separately from Botox or weight loss charts
- Staff trained on NAD+ administration, dosing range, and adverse reaction response
- A state-specific compliance check — supervision rules for IV therapy vary by state and by license type
The steps
1. Confirm your state's rules on IV nutrient therapy supervision
This determines everything downstream, including who can order NAD+ and whether an NP can operate independently or needs a collaborating physician's active sign-off. States with independent practice authority for NPs still often require a written protocol for infusion therapy. If your medspa already has state-specific oversight in place, review it against IV therapy specifically rather than assuming injectable coverage extends.
Common mistake: assuming the collaborating physician agreement you signed for Botox automatically extends to NAD+. It doesn't unless the agreement names infusion therapy.
2. Line up medical director oversight that covers NAD+ specifically
Your collaborating physician needs to review and sign off on NAD+ as a covered service, not just acknowledge it verbally. US Medical Directors works with medspas adding NAD+ IV therapy to structure this oversight so the physician relationship holds up if a state board asks for documentation. This step is the one most medspas underestimate — it's not a formality, it's the legal backbone of the whole service line.
Common mistake: treating medical director sign-off as a one-time email instead of a documented, dated agreement addendum.
3. Draft a NAD+-specific protocol and standing order
The standing order should cover dosing range, infusion rate, contraindications, and escalation steps if a patient has a reaction. Generic IV hydration protocols don't cover NAD+'s specific side-effect profile, which includes flushing and chest tightness during infusion that patients need to be warned about in advance.
Work with your collaborating physician to build this protocol before you schedule a single appointment. Collaborating physician agreements built specifically for medspas adding NAD+ IV therapy spell out exactly what the standing order needs to contain.
Common mistake: copying a generic IV hydration protocol template off the internet and swapping in "NAD+" without adjusting dosing and reaction guidance.
4. Set up good faith exams for every new NAD+ patient
Most states that regulate IV therapy require a documented exam before the first treatment, confirming the patient is a reasonable candidate and doesn't have contraindications like pregnancy or certain cardiac conditions. This exam needs to happen before the infusion, not retroactively logged after.
Good faith exams for medspas should be built into your intake flow so front desk staff know NAD+ patients route through the same compliance step as injectable patients, just with different exam criteria.
Common mistake: running the good faith exam for Botox but skipping it for NAD+ because it's "just vitamins." NAD+ is an IV drug therapy, not a supplement.
5. Build chart review into your NAD+ workflow
Every NAD+ infusion needs a chart entry documenting dose, infusion time, patient response, and any adverse events — separate from your injectable charting. Chart review catches missing documentation before a state audit does, and it's the single easiest thing to let slide once volume picks up.
Assign someone to review NAD+ charts on a set cadence, not "whenever someone remembers."
Common mistake: lumping NAD+ chart notes into the same template used for filler patients, which leaves out infusion-specific fields a reviewer or auditor will look for.
6. Train staff on administration and adverse reaction response
NAD+ infusions run longer than a typical injectable appointment, and patients sitting with an IV in for that stretch need a staff member who can recognize and respond to flushing, nausea, or chest discomfort immediately. Document the training date and who conducted it.
Common mistake: assuming injector-level training covers infusion monitoring. It doesn't — infusion therapy is a different skill set.
7. Price, schedule, and launch the service
Once oversight, protocol, good faith exams, and chart review are locked in, add NAD+ to your booking system and menu. Launch quietly first — a soft rollout to existing clients lets you catch workflow gaps before a marketing push brings in volume you're not ready to document properly.
Common mistake: launching NAD+ with a marketing campaign the same week the collaborating physician agreement gets signed, leaving no buffer to catch process gaps.
8. Schedule a compliance check-in 90 days after launch
Review your first quarter of NAD+ charts against your protocol. Confirm good faith exams were completed for every patient and that your collaborating physician has actually reviewed a sample of charts, not just signed the original agreement.
Common mistake: treating the initial compliance setup as "done" instead of an ongoing responsibility that needs periodic review.
Get NAD+ oversight structured right
Medical director support built for medspas adding IV nutrient therapy.
Troubleshooting
Your collaborating physician won't sign off on NAD+. Some physicians are comfortable with injectables but not IV infusion therapy. If yours declines, you need a collaborating physician whose scope explicitly includes infusion services — not every medical director wants that liability.
Your state doesn't allow NP-led IV therapy without direct physician involvement. Check your state's nurse practice act specifically for infusion therapy, since it's often stricter than the rules for injectables. This can change your staffing model for NAD+ entirely.
Good faith exams are backing up your launch timeline. Build the exam into intake scheduling from day one rather than trying to retrofit it once appointments are already booked.
Existing chart review process doesn't have a field for infusion details. Update your chart review template before launch, not after your first audit request.
Staff aren't confident recognizing an adverse reaction mid-infusion. Re-run training with real scenario walkthroughs, not just a written protocol handout.
Tools and resources
- Medical director support for NAD+ IV therapy clinics
- Collaborating physician agreements for medspas adding NAD+ IV therapy
- Good faith exams for medspas
- Medical director for IV hydration clinics
- How to structure a collaborating physician agreement
What to do next
Once NAD+ is running clean, most medspas look at whether their broader collaborating physician setup can scale to the next service line without renegotiating from scratch. Review your current agreement's scope language before you add anything else to the menu in 2026.
FAQ
Do I need a new collaborating physician agreement to add NAD+ IV therapy?
Yes, in most cases your existing agreement needs an addendum or a new agreement that specifically names IV nutrient therapy. A Botox-only agreement typically doesn’t cover infusion services in 2026.
Is a good faith exam required before NAD+ IV therapy?
Most states that regulate IV therapy require a documented exam before the first infusion, confirming the patient has no contraindications. This exam needs to happen before treatment, not logged retroactively.
Can a nurse practitioner order NAD+ IV therapy without a physician?
It depends on your state’s nurse practice act specifically for infusion therapy, which is often stricter than rules for injectables. Some independent-practice states still require a written protocol for IV drug administration.
What’s the difference between chart review for NAD+ and chart review for Botox?
NAD+ chart review needs infusion-specific fields like dose, infusion rate, and reaction monitoring that a standard injectable chart template doesn’t capture. Using the same template for both risks missing documentation an auditor looks for.
How long does it take to add NAD+ IV therapy to a medspa menu compliantly?
Timeline depends on how quickly your collaborating physician agreement can be updated and your good faith exam workflow set up, but rushing this step is the most common cause of compliance gaps. Most practices should treat oversight setup as the first task, not the last.
Does NAD+ IV therapy need its own standing order?
Yes, a generic IV hydration protocol doesn’t cover NAD+’s specific dosing range and side-effect profile. Your collaborating physician should sign a NAD+-specific standing order before the service launches.
What happens if a medspa adds NAD+ without proper medical oversight?
Practices risk state board complaints, particularly if an adverse reaction occurs and there’s no documented protocol or exam on file. Oversight gaps are far more likely to surface during a patient complaint than a routine inspection.
One last thing
The medspas that run into trouble with NAD+ almost never get flagged for the infusion itself — they get flagged because the paperwork trail doesn't match what actually happened in the treatment room. Build the documentation habit in month one, and it never becomes a problem in 2026 or any year after.
Related guides
- Medical director for mobile IV therapy businesses
- Chart review services for medspas
- How to document chart reviews for medical director compliance
- How to draft standing orders for aesthetic nurse practitioners
